Indogulf Cropsci Q1 FY27 Earnings Call — Analysis (NSE: IGCL)
Delayed monsoon and pricing headwinds led to an 11% YoY revenue drop to ₹168.5 Cr in Q1FY27, though gross margins expanded 600 bps on captive integration and product mix.
Result quality: poor — Revenue declined. Management sentiment: neutral.
The take
Q1FY27 Revenue from Operations ₹168.5 Cr ( -11.0% YoY ) . New guidance — FY31 revenue capacity target ₹1800 Cr . New story: Backward Integration & Gross Margin Expansion .
Results
Revenue ₹168.5 Cr -11% YoY (+12% QoQ); EBITDA ₹9.6 Cr -4% YoY with EBITDA margin at 5.7% (+50 bps YoY); PAT stood at ₹2.4 Cr (-38% YoY).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue from Operations | ₹168.5 Cr | -11.0% | yoy · Q1FY27 · Q1FY26 was ₹189.4 Cr |
| Revenue from Operations | ₹168.5 Cr | +11.7% | sequential · Q1FY27 · Q4FY26 was ₹150.8 Cr |
| Cost of Goods Sold | ₹122.0 Cr | -17.0% | yoy · Q1FY27 · Q1FY26 was ₹147.0 Cr |
| Gross Profit | ₹46.6 Cr | +11.8% | yoy · Q1FY27 · Q1FY26 was ₹41.7 Cr |
| Gross Margin | 28.0% | +600bps | yoy · Q1FY27 · Q1FY26 was 22.0% |
| EBITDA | ₹9.6 Cr | -3.0% | yoy · Q1FY27 · Q1FY26 was ₹9.9 Cr |
| EBITDA Margin | 5.7% | +50bps | yoy · Q1FY27 · Q1FY26 was 5.2% |
| Profit After Tax | ₹2.4 Cr | -38.5% | yoy · Q1FY27 · Q1FY26 was ₹3.9 Cr |
| PAT Margin | 1.4% | -70bps | yoy · Q1FY27 · Q1FY26 was 2.1% |
| Capital Work-in-Progress | ₹76.4 Cr | +33.8% | yoy · FY26 · FY25 was ₹57.1 Cr |
Guidance
Management targets reaching ₹1,800+ Cr in top line over the next 4-5 years post expansion of existing manufacturing infrastructure.
What management committed to
- With the expended capacity, [Indogulf Cropsciences] can go up to the top line of Rs. 1800 crores, reaching it in approximately 4-5 years. — Rs. 1800 crores, FY31
- With the existing capacity, [Indogulf Cropsciences] peak turnover should be around Rs. 1100 crores - Rs. 1200 crores. — Rs. 1100 crores - Rs. 1200 crores
- [Indogulf Cropsciences'] new fungicide remains on track for launch this quarter [Q2FY27], subject to the relevant patent expiry. — Q2FY27
- [Indogulf Cropsciences] has a three-year collaboration project with ICAR-IARI to develop heat resistance and drought resistance crop solutions. — 3-year project, FY29
- [Indogulf Cropsciences] does not plan to do direct marketing in Australia for the next one or two years. — FY28
Key themes
Monsoon disruption and margin resilience
How the narrative shifted
- Monsoon Timing and Agronomic Disruption: Delayed and uneven southwest monsoon postponed sowing and crop protection application windows, pushing early demand into Q2 and causing cautious channel stocking.
- Backward Integration & Gross Margin Expansion: Higher captive consumption of technicals (up to 34%) alongside procurement discipline drove gross margin up 600 bps YoY to 28% despite pricing deflation.
- Biologicals & Speciality Product Mix Shift: Transitioning from generic agrochemicals to an integrated agri-solution provider via biologicals, stress-tolerant inputs, and brand-level push (biologicals reaching 22% of brand sales).
- Global Regulatory Registrations and Export Strategy: Leveraging 189 global registrations to open export routes across LATAM, Africa, Middle East, and Asia to counterbalance domestic seasonality.
- Working Capital and Finance Cost Normalisation: Pre-season inventory build combined with slower Q1 liquidation raised finance costs, which are anticipated to decline as inventory clears in peak Kharif.
Operational commentary
- Capacity utilization improved to 70% in Q1FY27 compared to 52% in FY26, driven by operational ramp-up.
- Captive consumption of technicals expanded to 34% in Q1FY27 from ~22% previously, aiding margin resilience and raw material security.
- International registrations progress: Received Mancozeb 80% WP registration in Taiwan, import permission for Indo-Apache in Sri Lanka, and 5 technical registrations in Saudi Arabia (189 total global registrations, >120 active).
- Ongoing manufacturing capex: Barwasni plant expansion and development of Dry Flowable (DF) manufacturing facility underway.
- Revenue mix stood at 87% crop protection, 3% biologicals, 3% plant nutrients, and 7% others; channel mix at 47% B2C, 40% B2B, and 13% exports.
- Biologicals and plant nutrition share of brand sales expanded to 22% in Q1FY27 compared with 11% in Q1FY26.
Analyst Q&A
Q. Expected growth rate for FY27 and whether 15% top-line growth is achievable given the 19% growth in FY26?
Management declined to provide a specific percentage figure, citing challenging industry conditions in Q1 and El Nino impacts, while noting they are working aggressively to achieve growth.
Q. Peak turnover from current vs upcoming capacity and timeline to achieve ₹1,800 Cr revenue?
Current capacity can support ₹1,100-1,200 Cr turnover, while completed expansion capex will support ₹1,800+ Cr in approximately 4-5 years.
Q. Driver behind the 19% YoY rise in finance costs and expected run rate going forward?
Higher working capital and inventory stocking ahead of the season drove the rise; inventory liquidation and collections in near term are expected to bring finance costs down.
Q. Commercial strategy and updates regarding the Australian subsidiary (Indogulf Cropsciences Australia)?
The subsidiary is strictly an OECD registration-holding entity without near-term direct marketing plans, as focus remains on India, LATAM, Africa, and the Middle East.
Research and educational content only. Not investment advice.